158 related articles for article (PubMed ID: 3660436)
21. Serum bile acid profiles in cerebrotendinous xanthomatosis.
Beppu T; Seyama Y; Kasama T; Serizawa S; Yamakawa T
Clin Chim Acta; 1982 Feb; 118(2-3):167-75. PubMed ID: 7055978
[TBL] [Abstract][Full Text] [Related]
22. Chenodeoxycholic acid inhibits increased cholesterol and cholestanol synthesis in patients with cerebrotendinous xanthomatosis.
Salen G; Meriwether TW; Nicolau G
Biochem Med; 1975 Sep; 14(1):57-74. PubMed ID: 1212241
[No Abstract] [Full Text] [Related]
23. Increased plasma bile alcohol glucuronides in patients with cerebrotendinous xanthomatosis: effect of chenodeoxycholic acid.
Batta AK; Salen G; Shefer S; Tint GS; Batta M
J Lipid Res; 1987 Aug; 28(8):1006-12. PubMed ID: 3668385
[TBL] [Abstract][Full Text] [Related]
24. Capillary gas chromatographic determinations of urinary bile acids and bile alcohols in CTX patients proving the ineffectivity of ursodeoxycholic acid treatment.
Koopman BJ; Wolthers BG; van der Molen JC; Nagel GT; Waterreus RJ; Oosterhuis HJ
Clin Chim Acta; 1984 Sep; 142(1):103-11. PubMed ID: 6478619
[TBL] [Abstract][Full Text] [Related]
25. Determination of the glucurono-conjugated position in bile alcohol glucuronides present in a patient with cerebrotendinous xanthomatosis.
Kuramoto T; Suemura Y; Kihira K; Hiraoka T; Hoshita T
Steroids; 1995 Oct; 60(10):709-12. PubMed ID: 8539780
[TBL] [Abstract][Full Text] [Related]
26. Evidence for bile acid glucosides as normal constituents in human urine.
Marschall HU; Egestad B; Matern H; Matern S; Sjövall J
FEBS Lett; 1987 Mar; 213(2):411-4. PubMed ID: 2951276
[TBL] [Abstract][Full Text] [Related]
27. Cerebrotendinous xanthomatosis: a review of biochemical findings of the patient population in The Netherlands.
Koopman BJ; Wolthers BG; van der Molen JC; van der Slik W; Waterreus RJ; van Spreeken A
J Inherit Metab Dis; 1988; 11(1):56-75. PubMed ID: 3128689
[TBL] [Abstract][Full Text] [Related]
28. A case of cerebrotendinous xanthomatosis: effects of ursodeoxycholic acid administration on serum bile acids and cholestanol.
Kimura S; Beppu T; Kugai N; Koide Y; Fujita T; Iida K; Yamashita N; Yamashita K; Seyama Y
Jpn J Med; 1982 Jul; 21(3):210-5. PubMed ID: 7143816
[TBL] [Abstract][Full Text] [Related]
29. Bile acids and bile alcohols in a child with hepatic 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency: effects of chenodeoxycholic acid treatment.
Ichimiya H; Egestad B; Nazer H; Baginski ES; Clayton PT; Sjövall J
J Lipid Res; 1991 May; 32(5):829-41. PubMed ID: 2072042
[TBL] [Abstract][Full Text] [Related]
30. Determination of bile acids in biological fluids by liquid chromatography-electrospray tandem mass spectrometry.
Perwaiz S; Tuchweber B; Mignault D; Gilat T; Yousef IM
J Lipid Res; 2001 Jan; 42(1):114-9. PubMed ID: 11160372
[TBL] [Abstract][Full Text] [Related]
31. A biochemical abnormality in cerebrotendinous xanthomatosis. Impairment of bile acid biosynthesis associated with incomplete degradation of the cholesterol side chain.
Setoguchi T; Salen G; Tint GS; Mosbach EH
J Clin Invest; 1974 May; 53(5):1393-401. PubMed ID: 4825231
[TBL] [Abstract][Full Text] [Related]
32. Multicomponent analysis of bile acids in faeces by anion exchange and capillary column gas-liquid chromatography: application in oxytetracycline treated subjects.
Korpela JT; Fotsis T; Adlercreutz H
J Steroid Biochem; 1986 Aug; 25(2):277-84. PubMed ID: 3747527
[TBL] [Abstract][Full Text] [Related]
33. Conjugation, metabolism and excretion of [24-14C] chenodeoxycholic acid in patients with extrahepatic cholestasis before and after biliary drainage-analysis of conjugated bile acids by HPLC.
Hedenborg G; Norlander A; Norman A
Scand J Clin Lab Invest; 1985 Apr; 45(2):157-64. PubMed ID: 4001825
[TBL] [Abstract][Full Text] [Related]
34. [Congenital disorders of the bile acid metabolism (3 beta-hydroxy-delta 5-steroid dehydrogenase/isomerase deficiency, delta 4-3-oxosteroid 5 beta-reductase deficiency, cerebrotendinous xanthomatosis, and peroxisomal disorders].
Kondo KH; Maeda Y; Setoguchi T
Ryoikibetsu Shokogun Shirizu; 1995; (8):362-6. PubMed ID: 8581653
[No Abstract] [Full Text] [Related]
35. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration.
Nakagawa M; Colombo C; Setchell KD
Hepatology; 1990 Aug; 12(2):322-34. PubMed ID: 2391071
[TBL] [Abstract][Full Text] [Related]
36. Fecal bile acid analysis in healthy Japanese subjects using a lipophilic anion exchanger, capillary column gas chromatography and mass spectrometry.
Tanida N; Hikasa Y; Hosomi M; Satomi M; Oohama I; Shimoyama T
Gastroenterol Jpn; 1981; 16(4):363-71. PubMed ID: 7286561
[TBL] [Abstract][Full Text] [Related]
37. Treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid.
Pedley TA; Emerson RG; Warner CL; Rowland LP; Salen G
Ann Neurol; 1985 Oct; 18(4):517-8. PubMed ID: 4073846
[TBL] [Abstract][Full Text] [Related]
38. Hydrophilic 7 beta-hydroxy bile acids, lovastatin, and cholestyramine are ineffective in the treatment of cerebrotendinous xanthomatosis.
Batta AK; Salen G; Tint GS
Metabolism; 2004 May; 53(5):556-62. PubMed ID: 15131757
[TBL] [Abstract][Full Text] [Related]
39. The nature of urinary bile acid conjugates in patients with extrahepatic cholestasis.
Hedenborg G; Norman A
Scand J Clin Lab Invest; 1984 Dec; 44(8):725-33. PubMed ID: 6528216
[TBL] [Abstract][Full Text] [Related]
40. Psychiatric disorders in patients with cerebrotendinous xanthomatosis.
Berginer VM; Foster NL; Sadowsky M; Townsend JA; Siegel GJ; Salen G
Am J Psychiatry; 1988 Mar; 145(3):354-7. PubMed ID: 3344851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
